Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 34 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

6 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Phase 2
15(57.7%)
Phase 3
6(23.1%)
N/A
5(19.2%)
26Total
Phase 2(15)
Phase 3(6)
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (34)

Showing 20 of 34 trials
NCT06428487Phase 2Completed

Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Role: lead

NCT07542262Phase 2Enrolling By Invitation

Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers

Role: lead

NCT07523763Phase 2Active Not Recruiting

Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Role: lead

NCT07464470Recruiting

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers

Role: lead

NCT07448480Active Not Recruiting

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

Role: lead

NCT07448662Active Not Recruiting

Local Treatment Strategies for Brain Metastases of Colorectal Cancer

Role: lead

NCT07448493Active Not Recruiting

Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer

Role: lead

NCT07281001Not ApplicableRecruiting

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

Role: lead

NCT06967155Phase 2Active Not Recruiting

A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer

Role: lead

NCT07107217Phase 2Not Yet Recruiting

Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer

Role: lead

NCT06449989Recruiting

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

Role: lead

NCT06978400Phase 2Recruiting

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

Role: lead

NCT05939687Phase 3Recruiting

Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection

Role: lead

NCT06355921Not ApplicableNot Yet Recruiting

A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors

Role: lead

NCT05057143Not ApplicableRecruiting

3D Printed Implants for the Defect Reconstruction in Patients With Chest Wall Tumors

Role: lead

NCT05057195Not ApplicableRecruiting

Wide Excision of Soft Tissue Sarcomas in Combination With Interstitial Radiation Therapy

Role: lead

NCT05057130Phase 2Recruiting

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Role: lead

NCT05800197Unknown

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Role: lead

NCT05789771Completed

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

Role: lead

NCT05547529Phase 3Recruiting

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer

Role: lead